Last reviewed · How we verify
sIPV
sIPV is an inactivated polio vaccine that stimulates the immune system to produce antibodies against poliovirus types 1, 2, and 3.
sIPV is an inactivated polio vaccine that stimulates the immune system to produce antibodies against poliovirus types 1, 2, and 3. Used for Prevention of poliomyelitis (poliovirus types 1, 2, and 3).
At a glance
| Generic name | sIPV |
|---|---|
| Also known as | JNJ-64152348 |
| Sponsor | China National Biotec Group Company Limited |
| Drug class | Inactivated viral vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
sIPV (Sabin inactivated polio vaccine) is a trivalent inactivated vaccine derived from attenuated Sabin poliovirus strains that have been chemically inactivated. It is administered intramuscularly or intradermally to induce humoral and cellular immune responses against all three serotypes of poliovirus, providing protection against poliomyelitis. This vaccine formulation represents an alternative to the standard Salk IPV and is used in immunization programs.
Approved indications
- Prevention of poliomyelitis (poliovirus types 1, 2, and 3)
Common side effects
- Injection site pain or swelling
- Fever
- Myalgia
Key clinical trials
- Phase IV Clinical Study of Sequential Vaccination of Sabin Strain and Wild Strain Inactivated Poliovirus Vaccine (PHASE4)
- Phase IV Clinical Study of sIPV Administration in Adolescent and Adult Populations (PHASE4)
- Booster Dose of sIPV Co-administered With MMR and HepA-I. (PHASE4)
- the Five-year Antibody Persistence After Immunization With IPV, MMR and HepA-L Vaccines
- Phase III Clinical Trial of Sabin Strain Inactivated Poliovirus Vaccine (Vero Cell) (PHASE3)
- A Multi-center, Open-labelled, Randomized, Controlled, Extended Phase Ⅲ Clinical Trial of sIPV Vaccine (PHASE3)
- Study of Concomitant Administration of the sIPV and DTaP or MMR (PHASE4)
- Sequential Vaccination of Poliomyelitis Vaccine (Vero Cells), Inactivated, Sabin Strains From Different Manufacturers (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- sIPV CI brief — competitive landscape report
- sIPV updates RSS · CI watch RSS
- China National Biotec Group Company Limited portfolio CI